13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
30 檔
17.9%
According to the latest 13F quarterly dataset, Great Point Partners LLC managed an equity portfolio of $529.1M at the end of Q3 2025, spanning 30 distinct U.S. exchange-listed positions.
Great Point Partners LLC executed strategic sector rebalancing during Q3 2025, establishing 15 new positions while fully exiting 17 holdings and trimming 8 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 9.53% | -3.21% | -15.00% | |
| 2 | RZLT | Rezolute Inc | Stock-Other | 9.50% | +0.27% | -19.17% | |
| 3 | NKTR | Nektar Therapeutics | Stock-Other | 7.04% | -2.92% | — | |
| 4 | ✓ | Zura Bio LTD | Stock-Other | 6.81% | -1.07% | +20.37% | |
| 5 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.27% | — | — | |
| 6 | ASND | Ascendis Pharma A/S | Stock-Other | 6.15% | — | — | |
| 7 | ABVX | Abivax Sa-adr | Stock-Other | 5.25% | +15.22% | NEW | |
| 8 | APGE | Apogee Therapeutics Inc | Stock-Other | 4.98% | -7.23% | EXIT | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 4.31% | — | — | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 3.40% | — | — | |
| 11 | IMVT | Immunovant Inc | Stock-Other | 3.32% | -3.11% | EXIT | |
| 12 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 3.31% | — | — | |
| 13 | NGNE | Neurogene Inc | Stock-Other | 3.19% | -0.23% | -8.04% | |
| 14 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 2.92% | -0.50% | — | |
| 15 | UPB | Upstream Bio Inc | Stock-Other | 2.33% | — | — | |
| 16 | JBIO | Jade Biosciences Inc | Stock-Other | 2.25% | -3.11% | EXIT | |
| 17 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.16% | — | -84.00% | |
| 18 | AKRO | Akero Therapeutics Inc | Stock-Other | 2.03% | — | — | |
| 19 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.02% | — | — | |
| 20 | CNTX | Context Therapeutics Inc | Stock-Other | 1.87% | -1.35% | EXIT | |
| 21 | PHVS | Pharvaris N.V. | Stock-Other | 1.60% | -0.54% | EXIT | |
| 22 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.56% | +0.49% | NEW | |
| 23 | LEGN | Legend Biotech Corp-adr | Stock-Other | 1.53% | — | -67.58% | |
| 24 | ORKA | Oruka Therapeutics Inc | Stock-Other | 1.45% | +1.23% | — | |
| 25 | UNCY | Unicycive Therapeutics Inc | Stock-Other | 1.43% | -1.20% | EXIT | |
| 26 | SANA | Sana Biotechnology Inc | Stock-Other | 1.02% | — | — | |
| 27 | ABSI | Absci CORP | Stock-Other | 1.00% | — | — | |
| 28 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.97% | — | — | |
| 29 | PLRX | Pliant Therapeutics Inc | Stock-Other | 0.52% | — | — | |
| 30 | CAPR | Capricor Therapeutics Inc | Stock-Other | 0.26% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +8.2% | -19.17% | Add |
| 2 | AMLX | Amylyx Pharmaceuticals Inc | +6.1% | -15.00% | Trim |
| 3 | ✓ | Zura Bio LTD | +4.6% | +20.37% | Add |
| 4 | ASND | Ascendis Pharma A/S | +2% | — | Add |
| 5 | DNTH | Dianthus Therapeutics Inc | +1.7% | — | Trim |
| 6 | UPB | Upstream Bio Inc | +1.4% | — | Unchanged |
| 7 | CNTX | Context Therapeutics Inc | +0.4% | — | Unchanged |
| 8 | NGNE | Neurogene Inc | +0.3% | -8.04% | Trim |
| 9 | IMVT | Immunovant Inc | -0.1% | +90.71% | Add |
| 10 | PLRX | Pliant Therapeutics Inc | -0.1% | — | Unchanged |
| 11 | ABVX | Abivax Sa-adr | -0.2% | -88.39% | Trim |
| 12 | LEGN | Legend Biotech Corp-adr | -1% | -67.58% | Trim |
| 13 | XENE | Xenon Pharmaceuticals Inc | -1.1% | — | Trim |
| 14 | IONS | Ionis Pharmaceuticals Inc | -1.8% | -84.00% | Trim |
| 15 | CYTK | Cytokinetics Inc | -4.5% | — | Trim |
| 16 | NKTR | Nektar Therapeutics | — | NEW | New buy |
| 17 | SLNOEUR | Soleno Therapeutics Inc | — | NEW | New buy |
| 18 | APGE | Apogee Therapeutics Inc | — | NEW | New buy |
| 19 | 4XC1 | Kalvista Pharmaceuticals Inc | — | EXIT | Sold out |
| 20 | EOLS | Evolus Inc | — | EXIT | Sold out |
| 21 | VRDN | Viridian Therapeutics Inc | — | EXIT | Sold out |
| 22 | ✓ | Merus N V | — | EXIT | Sold out |
| 23 | AKBA | Akebia Therapeutics Inc | — | EXIT | Sold out |
| 24 | DVAX | Dynavax Technologies CORP | — | EXIT | Sold out |
| 25 | EPRX | Eupraxia Pharmaceuticals Inc | — | NEW | New buy |
| 26 | ✓ | — | EXIT | Sold out | |
| 27 | JBIO | Jade Biosciences Inc | — | NEW | New buy |
| 28 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 29 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 30 | SMMT | Summit Therapeutics Inc | — | EXIT | Sold out |
| 31 | PCVX | Vaxcyte Inc | — | EXIT | Sold out |
| 32 | AUTL | Autolus Therapeutics PLC | — | EXIT | Sold out |
| 33 | ✓ | Helix Acquisition CORP Ii | — | EXIT | Sold out |
| 34 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 35 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
| 36 | ORKA | Oruka Therapeutics Inc | — | NEW | New buy |
| 37 | UNCY | Unicycive Therapeutics Inc | — | NEW | New buy |
| 38 | BEAM | Beam Therapeutics Inc | — | EXIT | Sold out |
| 39 | ACLXGBX | Arcellx Inc | — | EXIT | Sold out |
| 40 | MREO | Mereo Biopharma Group Pl-adr | — | EXIT | Sold out |
| 41 | SANA | Sana Biotechnology Inc | — | NEW | New buy |
| 42 | ABSI | Absci CORP | — | NEW | New buy |
| 43 | HRMY | Harmony Biosciences Holdings | — | NEW | New buy |
| 44 | 260 | Centessa Pharmaceuticals-adr | — | EXIT | Sold out |
| 45 | VYGR | Voyager Therapeutics Inc | — | EXIT | Sold out |
| 46 | PMNEUR | Promis Neurosciences Inc | — | EXIT | Sold out |
| 47 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 30 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including AMLX, RZLT, NKTR) accounted for 17.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
NKTR
市值: $17.1M
Top Position Liquidated / Trimmed
4XC1
前期市值: $11.7M
During Q3 2025, Great Point Partners LLC's top holdings by market value included AMLX (9.5%)、RZLT (9.5%)、NKTR (7.0%). The largest single position, AMLX, represented 9.5% of total portfolio value.
In Q3 2025, Great Point Partners LLC made 44 total portfolio adjustments, initiating 15 new buys, adding to 4 positions, trimming 8 holdings, and fully liquidating 17 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.